Revolutionizing Immuno-oncology

We’re enabling antibody-based therapies to attack targets that are inside cells, such as mutated cancer-causing and viral proteins.

Cancer will have no place to hide

Affinity is a privately-owned biotechnology company based in Melbourne, Australia. Founded by biotechnology entrepreneurs Ben Kiefel and Matt Beasley in 2009, Affinity started to build and develop the world’s fastest antibody discovery platform. Affinity’s resulting technology, Retained DisplayTM (ReD), has since been tested in campaigns against some of the most difficult diagnostic and lab reagent targets the team could find.

In late 2016, industry veteran Pete Smith joined Affinity as CEO, and the team set their sights on developing therapeutic antibodies. Recognizing that ReD is best differentiated by its ability to hit difficult targets, Affinity focused on discovering antibodies specific for pMHCs – thereby enabling cells to be targeted on the basis of their expression of particular intracellular and secreted proteins. Initial screens proved highly successful and Affinity has since gone on to successfully identify high affinity and selective antibodies against numerous pMHCs, possibly more than the rest of the world combined.

Affinity is collaborating with some of the world’s leading institutions, working on a diverse range of targets, including endogenous retroviruses and patient-specific neoantigens. These collaborations have demonstrated the utility of Affinity’s human scFv in bispecific and CAR-T formats. Affinity’s strategy is to work with partners to develop therapeutics against specific targets while also establishing spin-outs or joint-ventures to clinically develop specific assets.

Our Team

Scientific publications

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Short headline
Short headline
Short headline

Our partners

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Partnering with us

Affinity is seeking partnerships to fully exploit the potential of its technology whilst also building an in-house portfolio of products.

Contact us